M. D’Amico

636 total citations
15 papers, 209 citations indexed

About

M. D’Amico is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, M. D’Amico has authored 15 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in M. D’Amico's work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Advanced Breast Cancer Therapies (3 papers). M. D’Amico is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Advanced Breast Cancer Therapies (3 papers). M. D’Amico collaborates with scholars based in Italy, Cuba and Norway. M. D’Amico's co-authors include L Belli, Marcello Vangeli, Giovambattista Pinzello, Alberto B. Alberti, G. F. Rondinara, E. Minóla, Luciano De Carlis, Aldo Airoldi, D Forti and Palma Fedele and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Annals of Oncology.

In The Last Decade

M. D’Amico

12 papers receiving 202 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. D’Amico Italy 5 126 117 36 32 31 15 209
Berta Caballol Spain 6 140 1.1× 176 1.5× 10 0.3× 25 0.8× 26 0.8× 18 234
Mengru Zhan China 9 225 1.8× 241 2.1× 45 1.3× 36 1.1× 8 0.3× 18 385
Marwa Salama Egypt 7 113 0.9× 126 1.1× 29 0.8× 49 1.5× 6 0.2× 10 217
Lea Nußbaum United Kingdom 5 45 0.4× 61 0.5× 40 1.1× 67 2.1× 14 0.5× 7 282
Xieer Liang China 12 229 1.8× 277 2.4× 14 0.4× 23 0.7× 5 0.2× 32 312
Ghada M. Salum Egypt 10 101 0.8× 109 0.9× 8 0.2× 54 1.7× 17 0.5× 28 235
Nasser Bayati United States 6 266 2.1× 259 2.2× 27 0.8× 23 0.7× 4 0.1× 9 325
Xue-Song Liang China 11 247 2.0× 280 2.4× 14 0.4× 65 2.0× 13 0.4× 31 403
Chifumi Sato Japan 13 339 2.7× 296 2.5× 26 0.7× 72 2.3× 16 0.5× 15 447
Marcela Galoppo Argentina 8 93 0.7× 133 1.1× 7 0.2× 20 0.6× 29 0.9× 9 188

Countries citing papers authored by M. D’Amico

Since Specialization
Citations

This map shows the geographic impact of M. D’Amico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. D’Amico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. D’Amico more than expected).

Fields of papers citing papers by M. D’Amico

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. D’Amico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. D’Amico. The network helps show where M. D’Amico may publish in the future.

Co-authorship network of co-authors of M. D’Amico

This figure shows the co-authorship network connecting the top 25 collaborators of M. D’Amico. A scholar is included among the top collaborators of M. D’Amico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. D’Amico. M. D’Amico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Orlando, Laura, Palma Fedele, Caterina Fontanella, et al.. (2015). Lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): a single center experience. Annals of Oncology. 26. vi17–vi17.
2.
Marino, Antonella, Stefania Eufemia Lutrino, P. Rizzo, et al.. (2015). Panitumumab after Progression on Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients: a Single Institution Experience. Tumori Journal. 101(5). 524–528. 3 indexed citations
3.
4.
Orlando, Laura, Palma Fedele, Nicola Calvani, et al.. (2012). Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment. Expert Opinion on Therapeutic Targets. 16(sup2). S83–S89. 6 indexed citations
5.
Marino, Antonella, P. Rizzo, Nicola Calvani, et al.. (2012). P-0230 Panitumumab after Progression on Cetuximab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (MCRC): A Single Institution Experience. Annals of Oncology. 23. iv95–iv96.
6.
Orlando, Laura, Palma Fedele, Nicola Calvani, et al.. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treatment Reviews. 36. S67–S71. 58 indexed citations
7.
Fedele, Palma, Laura Orlando, Antonella Marino, et al.. (2010). 22 ADHERENCE TO AND PERSISTENCE WITH AN ORAL METRONOMIC CHEMOTHERAPY WITH CAPECITABINE IN HEAVILY PRETREATED METASTATIC BREAST CANCER (MBC) PATIENTS. Cancer Treatment Reviews. 36. S101–S101. 3 indexed citations
8.
Orlando, Laura, Palma Fedele, Nicola Calvani, et al.. (2009). Adjuvant Endocrine Treatment in Premenopausal Early Breast Cancer. Oncology. 77(Suppl. 1). 9–13. 2 indexed citations
9.
Pasetto, Lara Maria, Sara Lonardi, C. Caroti, et al.. (2004). Phase I study of weekly oxaliplatin (OXA) + 5-fluorouracil continuous infusion (FU CI) in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3770–3770. 4 indexed citations
10.
Pasetto, Lara Maria, Sara Lonardi, C. Caroti, et al.. (2004). Phase I study of weekly oxaliplatin (OXA) + 5-fluorouracil continuous infusion (FU CI) in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology. 22(14_suppl). 3770–3770. 1 indexed citations
11.
Lonardi, Sara, Myriam Paris, C. Caroti, et al.. (2004). Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). Journal of Clinical Oncology. 22(14_suppl). 3577–3577. 3 indexed citations
12.
Lonardi, Sara, Myriam Paris, C. Caroti, et al.. (2004). Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). Journal of Clinical Oncology. 22(14_suppl). 3577–3577. 2 indexed citations
13.
Alberti, Alberto B., L Belli, Aldo Airoldi, et al.. (2001). Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transplantation. 7(10). 870–876. 71 indexed citations
14.
Vago, Luca, Pietro Zerbi, R. Caldarelli-Stefano, et al.. (2000). Polymerase Chain Reaction for Mycobacterium <i>tuberculosis</i> Complex DNA. Acta Cytologica. 44(6). 1023–1028. 6 indexed citations
15.
Bellati, G., M. Asti, Antonella Lisa, et al.. (1998). Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology. 27(6). 1678–1686. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Berta Caballol Breakdown of academic impact, for papers by Mengru Zhan Breakdown of academic impact, for papers by Marwa Salama Breakdown of academic impact, for papers by Lea Nußbaum Breakdown of academic impact, for papers by Xieer Liang Breakdown of academic impact, for papers by Ghada M. Salum Breakdown of academic impact, for papers by Nasser Bayati Breakdown of academic impact, for papers by Xue-Song Liang Breakdown of academic impact, for papers by Chifumi Sato Breakdown of academic impact, for papers by Marcela Galoppo
Rankless by CCL
2026